Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.
The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.
Overview
Viking Therapeutics (NASDAQ: VKTX) stock is down almost 66% from its early 2024 peak and down about 8.4% so far in 2026. While there's little the company can do regarding the drug development programs of larger peers like Eli Lilly and Novo Nordisk, Viking has a mix of near- and long-term catalysts in its pipeline that could meaningfully rerate the stock.
The company's lead drug candidate is VK2735, a dual GLP-1 and GIP agonist in development in subcutaneous and oral forms to treat obesity and type 2 diabetes. VK2735 has two potential advantages over rival drugs, including Eli Lilly's Zepbound/Mounjaro (tirzepatide), Foundayo (orforglipron), and Novo Nordisk's Ozempic/Wegovy (semaglutide).
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.